Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Colorectal Neoplasms 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 12Nivolumab 6Cyclophosphamide 6fludarabine 5Ipilimumab 4amatuximab 3Cisplatin 3tislelizumab 2spartalizumab 2fludarabine phosphate 2budigalimab 2belinostat 2Plicamycin 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorouracil 2Cytoreduction Surgical Procedures 2venetoclax 1tocilizumab 1talazoparib 1sotorasib 1rovalpituzumab tesirine 1obinutuzumab 1niraparib 1naptumomab estafenatox 1milademetan 1irinotecan sucrosofate 1epacadostat 1enzalutamide 1durvalumab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Mesothelioma × Automobiles × Gastrointestinal × Clear all
NCT01583686 2019-10-14

CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
15 enrolled 14 charts
GastrointestinalGynecologicOther solid neoplasmThoracic

Uterine Cervical Neoplasms, Lung Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡